ClinicalTrials.Veeva

Menu

Immunogenicity Assessment of Subjects Receiving Rabies Post-exposure Prophylaxis in Cambodia

P

Pasteur Institute of Cambodia

Status

Completed

Conditions

Rabies Post-exposure Prophylaxis

Treatments

Biological: Intradermal (ID) rabies post-exposure prophylaxis
Biological: Intramuscular (IM) rabies post-exposure prophylaxis

Study type

Observational

Funder types

Other
Industry

Identifiers

NCT05684185
RAB00056

Details and patient eligibility

About

A rabies virus neutralizing antibody (RVNA) concentration ≥ 0.5 IU/ml at 14 days after immunization is considered a proxy for protection in vaccine efficacy studies. Abridged and dose-sparing vaccination regimens increase accessibility and reduce both direct and indirect costs, especially in resource-constrained countries where RABV prevalence is highest. Several efficacy studies evaluated safety and immunogenicity of abridged regimens in healthy adult volunteers using either four-site intradermal (ID) or intramuscular (IM) regimens, showing them to be safe and immunogenic.

Researchers at the Institut Pasteur du Cambodge (IPC) have previously conducted a retrospective study on clinical outcome at ≥6 months in 3318 Cambodians who received intradermal Vero cell vaccine post-exposure prophylaxis after a bite by a rabid or sick-looking but untested dog in 2003-2014. Here, the investigators could show that there was no significant difference in survival among patients who received 3 versus 4 sessions of the Thai Red Cross (TRC) ID regimen. In a separate study, investigators measured antibody responses in order to evaluate the immunogenicity of the TRC regiment after 3 sessions versus 4 sessions. The investigators did not observe an increase in rabies virus seroneutralization titers 14 days after the fourth immunization compared to 14 days after the third immunization. These results contributed to changes endorsed by the WHO in its April 2018 guidelines. The "Institut Pasteur du Cambodge (IPC) regimen" of three PEP sessions of two-site ID 0.1 mL vaccine doses each at days 0, 3 and 7 is the first one-week PEP regimen to be recommended.

In the current research project, the aim is to compare further different PEP vaccination strategies in a real life setting of individuals attending the rabies vaccination center at Institut Pasteur du Cambodge (IPC) in Phom Penh, Cambodia. The antibody kinetics and cellular immune responses in patients following either the one-week, 2-site ID regimen (IPC regimen) or the two-week IM regimen (4-dose regimen) as well as the participants' survival for both protocols after 6 months are evaluated.

Enrollment

215 patients

Sex

All

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Subjects entering a rabies post-exposure vaccination course whatever the vaccine used with or without administration of rabies immunoglobulin (RIGs).
  • Subjects with ability to attend all scheduled visits and to comply with all study procedures

Exclusion criteria

  • Subjects with history of previous rabies vaccination

Trial design

215 participants in 4 patient groups

IM, <15 years old
Description:
Group with Intramuscular (IM) rabies post-exposure prophylaxis
Treatment:
Biological: Intramuscular (IM) rabies post-exposure prophylaxis
IM, 15 years old and older
Description:
Group with Intramuscular (IM) rabies post-exposure prophylaxis
Treatment:
Biological: Intramuscular (IM) rabies post-exposure prophylaxis
ID, <15 years old
Description:
Group with Intradermal (ID) rabies post-exposure prophylaxis
Treatment:
Biological: Intradermal (ID) rabies post-exposure prophylaxis
ID, 15 years old and older
Description:
Group with Intradermal (ID) rabies post-exposure prophylaxis
Treatment:
Biological: Intradermal (ID) rabies post-exposure prophylaxis

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems